As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.
New clues about the immune system response to MCC may be able to help guide future treatment strategies.
Dermatologists have long warned tan seekers about the detrimental effects of ultraviolet exposure and tanning beds, strongly discouraging their use; nasal tanning sprays are no different.
A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.
Recent research highlighted the important role of the skin’s microbiota in maintaining the homeostasis of the skin and the potential role the human microbiota may play in the development of skin cancer.
The commander-in-chief’s cancerous tissue was successfully removed last month.
Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.
Researchers said the pandemic played a role in healthcare providers’ ability to safely and promptly treat various skin cancers.
In a recent review, authors explored the effects of targeted therapies and immune checkpoint inhibitors on melanoma, particularly in minimal residual disease.
Catch up on the innovative pearls shared at the 2023 American College of Mohs Surgery including strategies to enhace the patient experience, the role artificial intelligence plays in dermatologic care, and more.
Leading clinicians debunk 5 of the most common sunscreen myths.
Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.
Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.
A poster presentation from the 19th Annual Skin of Color Society Scientific Symposium analyzed the differences in presentation of cutaneous melanoma among Asian American and Pacific Islander patients.
The clinical presentations of Merkel cell carcinoma in patients with skin of color require dermatology providers to be more aware of the nuances in diagnosis and management.
Both companies are hoping to make a positive impact in the neoadjuvant setting of cutaneous squamous cell carcinoma.
Although rare, clinicians are encountering more pediatric patients who are at an increased risk of skin cancer due to immunosuppression.
Rescue workers had a higher rate of malignant melanoma between 2005 and 2015 compared to the general population of New York State.
Frequent fliers, including pilots and cabin crew, are exposed to greater levels of UV and cosmic ionizing radiation than the general population, leading to higher incidence of skin cancers.
Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.
The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.
Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.
ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.
At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.
The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.
For all skin cancer news, click here.